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Abstract
Parkin is an E3 ubiquitin ligase, mutations in which cause Autosomal Recessive Parkinson’s Disease. Many studies aimed at
understanding Parkin function, regulation and dysfunction are performed using N-terminal epitope tags. We report here
that the use of small tags such as FLAG, cMyc and HA, influence the physical stability and activity of Parkin in and out of
cells, perturbing the autoinhibited native state of Parkin, resulting in an active-for-autoubiquitination species.
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Introduction
Parkin is a RING E3 ubiquitin ligase [1,2,3] which, in
conjunction with a ubiquitin-activating enzyme (E1) and a
ubiquitin-conjugating enzyme (E2), catalyses the attachment of
ubiquitin to itself and to multiple putative substrates [4,5,6].
Mutations occur throughout the gene sequence of Parkin, and
include exon deletions, duplications and rearrangements, trunca-
tions, and point mutations. Mutations in Parkin account for ,50%
of Autosomal Recessive Juvenile Parkinson’s Disease (ARJPD),
making it the largest known hereditary factor in Parkinson’s
Disease [7,8,9,10,11]. Since the discovery of Parkin and its E3
ubiquitin ligase activity, Parkin has been the subject of intensive
research efforts to understand its biology, substrates and
consequences of pathogenic mutations. To date, Parkin is reported
to have over 25 putative substrates, including itself, and has been
shown to be regulated by an array of posttranslational modifica-
tions and interaction with deubiquitinases [12,13,14,15,16,17,18]
and to mediate mitophagy [19,20,21,22,23]. Much of the research
into Parkin, both in cells and in vitro, has been carried out using N-
terminally tagged forms of Parkin. Depending on the study, the tag
is to aid detection and visualisation, or the tag is a large protein
fusion to aid in solubility and purification (for examples see
[1,2,3,13,24,25,26,27,28,29,30,31]). Fusion tags can vary greatly
in size, from large tags such as Glutathione-S-Transferade (GST),
Maltose Binding Protein (MBP) and Small Ubiquitin-like Modifier
(SUMO), 26 kDa, 43 kDa and 13 kDa respectively, to small
peptide tags including cMyc, FLAG and HA, each around 1 kDa
(Figure 1). Recently, we demonstrated that wild type native Parkin
exists in an autoinhibited state not competent for autoubiquitina-
tion [31]. Among other findings, we observed that MBP-, GST-,
or SUMO-tagged Parkin was constitutively active, suggesting a
disruption of the autoinhibited state. This was perhaps unsurpris-
ing given the large size of the fusion tags. However, the majority of
cell-based studies of Parkin utilise small peptide epitope tags and
the effect of these tags on Parkin activity and stability is unknown.
Therefore we set out to determine the influence commonly-used
cMyc, FLAG, and HA peptide tags have on the autoinhibited
nature and stability of Parkin. We report here that small epitope
tags fused to the N-terminus of Parkin also disrupt Parkin
autoinhibition and Parkin stability.
Results
N-terminal tags reduce Parkin stability
We expressed and purified to homogeneity cMyc-, FLAG-, and
HA-tagged full length Parkin. In order to determine the effects of
each peptide tag on the conformation and stability of Parkin, each
protein was subjected to a limited proteolysis using subtilisin.
cMyc- or FLAG-tagged Parkin are proteolysed in a similar pattern
to wild type Parkin, suggesting that these tags do not impact the
proteolytic susceptibility of Parkin (Figure 2A). In contrast, HA-
tagged Parkin increases Parkin susceptibility to the protease, from
the observation that HA-Parkin is digested at a lower concentra-
tion of protease in comparison to wild type Parkin. In addition to
the limited proteolysis, we assayed the thermal stability of each
species. A thermal denaturation experiment revealed the melting
temperature of wild type, cMyc-, FLAG- and HA-tagged Parkin to
be 56.5uC, 54.5uC, 56.0uC and 54.0uC respectively, revealing that
cMyc- and HA-Parkin (but not FLAG-Parkin) have reduced
thermal stability in comparison to wild type Parkin (Figure 2B).
Taken together, these results indicate that the cMyc-, FLAG- and
HA-tagged epitope tagged Parkin species are not in a fully native
conformation as assessed by susceptibility to proteolysis and
thermal denaturation.
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Previous work from ourselves and others [26,28,31] has
revealed that the N-terminal fusion of large proteins to Parkin
results in a form of Parkin active for autoubiquitination. In order
to test whether the same is true for small peptide tags we tested
each species in an in vitro autoubiquitination assay. As expected,
wild type native Parkin shows no autoubiquitination activity
(Figure 3A). In contrast, cMyc-, FLAG- and HA-tagged Parkin are
all heavily ubiquitinated, as seen by the formation of higher
molecular weight species (Figure 3A). These data suggest that the
presence of each of the N-terminal tags affects the autoinhibited
state of the wild type protein. We also tested His-Parkin,
commercially available from Boston Biochem. It is sold as a
positive control for autoubiquitination and is purified in inclusion
bodies and refolded (personal communication). In our hands it is
active for autoubiquitination, as advertised (Figure 3B). This may
be due to the disruption to the native state of Parkin caused by
refolding, or due to the N-terminal His-tag.
N-terminally tagged Parkin is active in cells
Given the effect on in vitro auto-ubiquitination of Parkin the N-
terminal tags have, we hypothesised that the same would be true in
an in vivo setting. To test this theory cMyc, FLAG and HA tags
were cloned onto the N-terminus of wild type Parkin in a
mammalian expression system. HEK293 cells were used to co-
express these constructs along with His6-ubiquitin either in the
presence of the proteasomal inhibitor MG132 or DMSO as a
control. All ubiquitinated species were pulled out using nickel
affinity chromatography and probed by western blotting using an
anti-Parkin antibody to visualise any ubiquitination of Parkin
(Figure 4, top panel). Analysis of the soluble lysates reveals how
each of the different Parkin species are stabilised in the presence of
MG132 (Figure 4, middle panel). Addition of proteasomal
Figure 1. Chemical composition of small epitope tags. (A) The chemical composition of the cMyc tag, (B) the FLAG tag, and (C) the HA tag.
The three-letter code amino acid sequence is shown beneath each linear representation.
doi:10.1371/journal.pone.0034748.g001
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by the high molecular weight laddering (Figure 4, top panel).
Although wild type Parkin exhibits a small amount of ubiquitina-
tion, addition of the tags to the protein has a significant impact on
the levels of ubiquitination seen; in particular, cMyc- and HA-
tagged Parkin display high levels of ubiquitination relative to wild
type untagged Parkin.
Discussion
Many cell-based studies of Parkin function depend upon reliable
detection by antibodies. One of the most established techniques for
achieving high-affinity detection is to tag the protein of interest
with an epitope recognised with high specificity by an antibody. As
well as being useful tools in understanding biological processes,
Figure 2. Epitope-tagged Parkin species are not in a native conformation. (A) Limited proteolytic digest of Parkin species in the presence of
increasing concentrations of subtilisin (w/w). The boxed area indicates the degradation of each species. The graph below shows the quantification of
the gels with each species normalised to the total amount of full-length species present in the absence of subtilisin. Each curve is coloured according
to the key. (B) Difference scanning fluorimetry of each Parkin species, with each thermal denaturation curve coloured according to the key and
melting points (Tm) of each protein indicated.
doi:10.1371/journal.pone.0034748.g002
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clearly shows that N-terminal epitope tagging of Parkin, a
commonly-used technique in the Parkin field, leads to physical
changes in the stability and activity of Parkin, that are also
observed in a cellular environment. Indeed, even modest changes
in protein stability can translate to a more substantial impact on
Parkin activity. Our work highlights the caveats involved in
working with epitope-tagged Parkin, namely that it is not wild
type. Previous work has specifically highlighted the ability of
Parkin to use fusion tags as pseudosubstrates, for example MBP
fused to Parkin has been shown to be ubiquitinated [28,31]. This
phenomenon is not unique to Parkin, or indeed E3 ligases, as a
mass spectrometric analysis approach has also shown how fusion
of a specific E2 to a GST-tag leads to ubiquitination of the GST
tag on multiple lysine residues [32]. It is conceivable that there are
more examples of tags being ubiquitinated that do not result in
publication.
In our previous study we identified an interaction between the
N-terminal ubiquitin-like (Ubl) domain of Parkin and a motif in
the C-terminus [31]. It is feasible that the addition of a tag to the
Ubl domain disrupts this intramolecular interaction, thus resulting
in the release of the autoinhibition. Many studies that employ
endogenous Parkin do not report the robust autoubiquitination of
Parkin, in contrast to that seen in tagged-Parkin studies
[15,33,34,35,36,37]. In addition, there have been reports that
Parkin can be alternatively transcribed after, or processed by
cleavage of, the Ubl domain [38,39]. When N-terminal epitope
tags are employed, these species remain undetected.
Taking our results into consideration, efforts should be made to
ensure the presence of a tag does not interfere with the native
behavioural properties of the protein of interest. Results obtained
using tagged proteins should be carefully controlled and
interpreted with caution, taking into consideration changes to
the protein’s natural state upon addition of a fusion tag.
Materials and Methods
Expression and purification of proteins
cMyc, FLAG and HA were cloned directly onto the N-terminus
of full length wild type Parkin in the pET SUMO vector using the
PhusionH mutagenesis kit (Finnzymes). Tagged proteins were
expressed in the same way as wild type Parkin, essentially as
described in [31]. Briefly, Luria Broth growth medium was
supplemented with 500 mM zinc chloride and cultures were grown
at 37uC until OD600 0.4. After reducing the temperature to 16uC,
cells were grown to OD600 0.8 before inducing with 25 mM
Isopropyl b-D-1-thiogalactopyranoside (IPTG). Cells were har-
vested, sonicated and clarified before affinity purification using Ni-
NTA resin (QIAGEN) and further purification on a gel filtration
column following overnight cleavage with the SUMO protease,
Ulp1. Proteins were flash frozen and stored in 50 mM Tris pH 8,
200 mM NaCl, 250 mM TCEP and 10% (v/v) glycerol.
Proteolysis and thermal stability assays
Proteolytic susceptibility of each Parkin species was tested by
adding 0.025, 0.050, 0.100 and 0.250 (w/w) % of Subtilisin A to
10 mg of Parkin in a total reaction volume of 20 ml. Reactions were
incubated at 4uC for 3 hours before stopping with 20 ml of SDS-
loading buffer. Gels were stained with SimplyBlue (Invitrogen).
Thermal stability assays were performed on an iQ5 iCycler
(BioRad) in a 96 well plate format using a temperature gradient
from 4uC to 100uC with 0.5uC increments. Each 100 ml reaction
contained 5 mg of Parkin buffered with 50 mM Tris pH 7.5,
Figure 3. Epitope tags disrupt Parkin autoinhibition in vitro. (A) Western blot analysis of the autoubiquitination of wild type and cMyc-,
FLAG, and HA-tagged Parkin. A truncation lacking the Ubl domain (DUblD) is the positive control. Ubiquitin conjugates are detected using anti-Parkin
(left) and anti-His-Ub (right). (B) Western blot analysis of the autoubiquitination of Boston Biochem’s His-Parkin, probed with anti Parkin (left) and
anti-His-Ub (right). Ubiquitin conjugates are indicated.
doi:10.1371/journal.pone.0034748.g003
Figure 4. Epitope tags influence Parkin ubiquitination in cells.
Western blot analysis of the ubiquitination of wild type and cMyc-,
FLAG-, and HA-tagged Parkin in HEK293 cells. His-ubiquitin-conjugates
were pulled out using nickel affinity and analysed using anti-Parkin (top
panel). Soluble lysates were probed for levels of Parkin (middle panel)
and actin levels are used as a loading control (bottom panel).
doi:10.1371/journal.pone.0034748.g004
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(TCEP). SYPRO Orange (Invitrogen) fluorescent dye was added
to each reaction to a 1/200 dilution. Results are plotted in
arbitrary units of the differential of the fluorescence divided by the
differential of the temperature versus the temperature. The
inflection point of the curve relates to the melting temperature
of the protein.
In vitro auto-ubiquitination assay
Autoubiquitination assays were carried out as described in [31].
Briefly, 15 nM UBE1, 1.1 mM UBE2L3, 5 mM His6-ubiquitin and
4 mM ATP in a reaction buffer consisting of 50 mM Tris pH 7.5,
2 mM DTT, 5 mM MgCl2 and 5% glycerol were mixed with
0.77 mM of each full length Parkin species before incubating at
37uC for 60 min. The 25 ml final reaction volume was stopped
with 12.5 ml SDS-loading buffer. Samples were subjected to
western blotting as follows: 1.3 ml loaded for visualisation with
anti-Parkin (1/5000, 1A1, IBL) and 6 ml loaded for visualisation
with anti-6xHis (1/2000, GE Healthcare).
In vivo ubiquitination assay
Full length WT Parkin, cMyc-Parkin, FLAG-Parkin and HA-
Parkin were cloned into the GatewayH destination vector
pcDNA_DEST40 (Invitrogen) following the GatewayH technology
manual. The His6-Ubiquitin mammalian construct was a kind gift
from Dr Axel Behrens (London Research Institute). See [31] for
detailed protocol. Briefly, HEK293 cells were transfected with
4 mg His6-Ubiquitin and 2 mg of either empty vector or a Parkin
containing vector using Effectene reagents (QIAGEN) according
to the manufacturers protocol. During the 48 hr incubation, cells
were treated with either 10 mM DMSO or 10 mM MG132
(Calbiochem) for 12 hr. Clarified soluble lysates were collected
and protein levels quantified. 100 mg of each sample was loaded
onto a gel for western blotting analysis using anti-Parkin (1/5000,
1A1, IBL) and anti-Actin (1/400, abcam) as a loading control.
His6-ubiquitinated species were affinity purified from soluble lysate
containing a total of 7 mg of protein using Ni-NTA magnetic
beads (QIAGEN). Samples were analysed by western blot using
anti-6xHis (1/2000, GE Healthcare).
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